Compare Hims and Hers Health Inc (HIMS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Recursion Pharmaceuticals Inc — how do they compare? Hims and Hers Health Inc trades at $29.34 (market cap $6.55B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Hims and Hers Health Inc is far larger — about 3.1× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 14,842,814). Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HIMS | RXRX | |
|---|---|---|
Market Cap | $6.55B | $2.14B |
Volume | 14,842,814 | 30,789,535 |
Sector | Health | Health |
52-Week High | $62.76 | $6.79 |
52-Week Low | $14.52 | $2.84 |
Typical Hold Time | 21 Days | 22 Days |
Enterprise Value | $7.25B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
